An update of the blockade of the renin angiotensin aldosterone system in clinical practice (Q38590227)

4 September 2017

title

An update of the blockade of the renin angiotensin aldosterone system in clinical practice (English)

1 reference

4 September 2017

Gema Ruiz-Hurtado

2

0 references

Luis Miguel Ruilope

object named as

Luis M Ruilope

series ordinal

3

0 references

author name string

Diego F Márquez

series ordinal

1

1 reference

4 September 2017

Julián Segura

series ordinal

4

1 reference

4 September 2017

language of work or name

English

0 references

publication date

7 September 2015

1 reference

Expert Opinion on Pharmacotherapy

4 September 2017

published in

1 reference

4 September 2017

volume

16

1 reference

4 September 2017

issue

15

1 reference

4 September 2017

page(s)

2283-2292

1 reference

Blood pressure parameters and risk of fatal stroke, NHANES II mortality study

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

New drugs, procedures, and devices for hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Comparison of agents that affect aldosterone action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Does cardiovascular protection translate into renal protection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Novel RAAS agonists and antagonists: clinical applications and controversies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Renal function and target organ damage in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Combined angiotensin inhibition for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Efficacy and tolerance of spironolactone in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Current challenges in the clinical management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Effects of eplerenone versus losartan in patients with low-renin hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Resistant hypertension and aldosterone: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Mineralocorticoid receptor blockade in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Angiotensin-neprilysin inhibition versus enalapril in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Prediction and management of hyperkalemia across the spectrum of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

A possible mechanism for the progression of chronic renal disease and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

Increase in plasma aldosterone during prolonged captopril treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1079623

10.1517/14656566.2015.1079623

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference